TRANSGENIC SOYBEAN FORMULA TO ENHANCE RESECTION-INDUCED INTESTINAL ADAPTATION

描述（由申请人提供）：短肠综合征（SGS）是由大量肠道切除术引起的，这在广泛的医学和外科治疗中经常是必要的。在大量小肠切除（SBR）后，残肠中发生一种称为适应的代偿过程。这种反应主要是一个有丝分裂的信号，最终导致绒毛变高，隐窝变深，粘膜吸收和消化表面积扩大。如果这种反应不充分，SGS患者一生中需要静脉营养，这就强调了适应的重要性。已经证明了

DESCRIPTION (provided by applicant): Short gut syndrome (SGS) results from the massive intestinal resection that is often necessary in a broad array of medical and surgical treatments. Following a massive small bowel resection (SBR), a compensatory process occurs in the remnant bowel termed adaptation. This response is largely a mitogenic signal culminating in taller villi, deeper crypts, and an expanded mucosal absorptive and digestive surface area. The significance of adaptation is underscored by the requirement in SGS patients of nutrition by vein for the duration of the patient's lifetime if this response is inadequate. It has been demonstrated that exogenous EGF enhances several morphologic parameters of adaptation and its use has been proposed as a treatment for SGS. A unique collaboration between researchers at the Donald Danforth Plant Science Center and physician scientists at the St. Louis Children's Hospital and Washington University School of Medicine will develop and do animal testing of a soy-milk formula produced from soybeans genetically engineered to synthesize EGF. This novel transgenic EGF soy-based formula may provide a low-cost, minimal-risk therapy for SBR patients as a means to reduce SGS. Plant-based production would have many advantages in terms of production costs, world-wide distribution, and stability. This approach may provide a simple means of reducing SGS, and the associated high-cost most often borne by public resources.